Skip to main content
Top
Published in: Journal of Neuro-Oncology 3/2016

01-09-2016 | Clinical Study

The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma

Authors: Arian Lasocki, Frank Gaillard, Mark A. Tacey, Katharine J. Drummond, Stephen L. Stuckey

Published in: Journal of Neuro-Oncology | Issue 3/2016

Login to get access

Abstract

Improvements in imaging are increasing the detection of multiple lesions in the setting of glioblastoma. Occasionally distant non-enhancing lesions may be identified which have the appearances of a multicentric low-grade glioma. We aimed to determine the incidence, prognostic significance and diagnostic value of this appearance in new glioblastoma patients. Pre-operative MRIs of patients with a new diagnosis of glioblastoma were reviewed to identify multicentric non-enhancing lesions, defined as areas of FLAIR hyperintensity and mass effect, without post-contrast enhancement, separate from the histologically-proven glioblastoma. Patient survival was compared to glioblastoma patients without these appearances, and follow-up imaging was reviewed. Nine of 151 patients (6 %) had multicentric non-enhancing lesions. Their median survival of 183 days was significantly worse than the 278 days for patients without multicentric nonenhancing lesions (p = 0.025). Follow-up MRIs were performed in four patients. In one patient, there were several additional lesions, one of which developed evidence of necrosis within 22 days of presentation. In the other three patients, the multicentric lesions developed enhancement and evidence of necrosis within 1 year, and became confluent on FLAIR with the dominant lesion. The appearance of a multicentric non-enhancing lesion is an uncommon finding in glioblastoma, but a poor prognostic feature. These lesions progress faster than expected for a low-grade glioma and are thus likely to represent more advanced lesions than their appearances suggest. Confluence with the dominant lesion developing with time suggests that the tumor is more extensive than appreciated on imaging.
Literature
3.
go back to reference Hassaneen W, Levine NB, Suki D, Salaskar AL, de Moura Lima A, McCutcheon IE, Prabhu SS, Lang FF, DeMonte F, Rao G, Weinberg JS, Wildrick DM, Aldape KD, Sawaya R (2011) Multiple craniotomies in the management of multifocal and multicentric glioblastoma. J Neurosurg 114(3):576–584. doi:10.3171/2010.6.JNS091326 CrossRefPubMed Hassaneen W, Levine NB, Suki D, Salaskar AL, de Moura Lima A, McCutcheon IE, Prabhu SS, Lang FF, DeMonte F, Rao G, Weinberg JS, Wildrick DM, Aldape KD, Sawaya R (2011) Multiple craniotomies in the management of multifocal and multicentric glioblastoma. J Neurosurg 114(3):576–584. doi:10.​3171/​2010.​6.​JNS091326 CrossRefPubMed
4.
go back to reference Salvati M, Cervoni L, Celli P, Caruso R, Gagliardi FM (1997) Multicentric and multifocal primary cerebral tumours. Methods of diagnosis and treatment. Ital J Neurol Sci 18(1):17–20. doi:10.1007/bf02106225 CrossRefPubMed Salvati M, Cervoni L, Celli P, Caruso R, Gagliardi FM (1997) Multicentric and multifocal primary cerebral tumours. Methods of diagnosis and treatment. Ital J Neurol Sci 18(1):17–20. doi:10.​1007/​bf02106225 CrossRefPubMed
6.
7.
go back to reference Lasocki A, Tsui A, Tacey MA, Drummond KJ, Field KM, Gaillard F (2015) MRI grading versus histology: predicting survival of World Health Organization grade II-IV astrocytomas. Am J Neuroradiol 36(1):77–83. doi:10.3174/ajnr.A4077 CrossRefPubMed Lasocki A, Tsui A, Tacey MA, Drummond KJ, Field KM, Gaillard F (2015) MRI grading versus histology: predicting survival of World Health Organization grade II-IV astrocytomas. Am J Neuroradiol 36(1):77–83. doi:10.​3174/​ajnr.​A4077 CrossRefPubMed
8.
go back to reference Barajas RF, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, Parsa AT, Aghi MK, McDermott MW, Berger MS, Cha S, Chang SM, Nelson SJ (2012) Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neurooncol 14 (7):942–954. doi:10.1093/neuonc/nos128 Barajas RF, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, Parsa AT, Aghi MK, McDermott MW, Berger MS, Cha S, Chang SM, Nelson SJ (2012) Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neurooncol 14 (7):942–954. doi:10.​1093/​neuonc/​nos128
9.
go back to reference Tang C, Guo J, Chen H, Yao C-J, Zhuang D-X, Wang Y, Tang W-J, Ren G, Yao Y, Wu J-S, Mao Y, Zhou L-F (2015) Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by (1)H-magnetic resonance spectroscopy. Int J Clin Exp Pathol 8(5):5327–5335PubMedPubMedCentral Tang C, Guo J, Chen H, Yao C-J, Zhuang D-X, Wang Y, Tang W-J, Ren G, Yao Y, Wu J-S, Mao Y, Zhou L-F (2015) Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by (1)H-magnetic resonance spectroscopy. Int J Clin Exp Pathol 8(5):5327–5335PubMedPubMedCentral
10.
go back to reference Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Am J Neuroradiol 33(7):1349–1355. doi:10.3174/ajnr.A2950 CrossRefPubMed Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Am J Neuroradiol 33(7):1349–1355. doi:10.​3174/​ajnr.​A2950 CrossRefPubMed
12.
go back to reference Jain R, Poisson LM, Gutman D, Scarpace L, Hwang SN, Holder CA, Wintermark M, Rao A, Colen RR, Kirby J, Freymann J, Jaffe CC, Mikkelsen T, Flanders A (2014) Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology 272(2):484–493. doi:10.1148/radiol.14131691 CrossRefPubMedPubMedCentral Jain R, Poisson LM, Gutman D, Scarpace L, Hwang SN, Holder CA, Wintermark M, Rao A, Colen RR, Kirby J, Freymann J, Jaffe CC, Mikkelsen T, Flanders A (2014) Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology 272(2):484–493. doi:10.​1148/​radiol.​14131691 CrossRefPubMedPubMedCentral
13.
go back to reference Muccio C, Tarantino A, Esposito G, Cerase A (2011) Differential diagnosis by unenhanced FLAIR T2-weighted magnetic resonance images between solitary high grade gliomas and cerebral metastases appearing as contrast-enhancing cortico-subcortical lesions. J Neurooncol 103(3):713–717. doi:10.1007/s11060-010-0454-8 CrossRefPubMed Muccio C, Tarantino A, Esposito G, Cerase A (2011) Differential diagnosis by unenhanced FLAIR T2-weighted magnetic resonance images between solitary high grade gliomas and cerebral metastases appearing as contrast-enhancing cortico-subcortical lesions. J Neurooncol 103(3):713–717. doi:10.​1007/​s11060-010-0454-8 CrossRefPubMed
15.
go back to reference Tang YM, Ngai S, Stuckey S (2006) The solitary enhancing cerebral lesion: can FLAIR aid the differentiation between glioma and metastasis? Am J Neuroradiol 27(3):609–611PubMed Tang YM, Ngai S, Stuckey S (2006) The solitary enhancing cerebral lesion: can FLAIR aid the differentiation between glioma and metastasis? Am J Neuroradiol 27(3):609–611PubMed
Metadata
Title
The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma
Authors
Arian Lasocki
Frank Gaillard
Mark A. Tacey
Katharine J. Drummond
Stephen L. Stuckey
Publication date
01-09-2016
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-016-2193-y

Other articles of this Issue 3/2016

Journal of Neuro-Oncology 3/2016 Go to the issue